University of Oklahoma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Oklahoma sits in the top decile of US sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count).
University of Oklahoma: 358 sponsored US clinical trials, 80 recruiting.
University of Oklahoma sponsors 358 registered US clinical trials on ClinicalTrials.gov, 80 of them currently recruiting, and 196 completed. 26 of these trials are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 6 trials.
Top-decile sponsor footprint
University of Oklahoma ranks in the top decile of sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 240 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
358 total, page 3 of 8
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
NCT01580241
Topical CBD Scar Outcomes Study
NCT05650697
Improving Sleep, Fatigue, Activity & Quality of Life in Cancer Survivors Via a Transdiagnostic Intervention
NCT07023783
Impact of Chia Seeds on Human Breast Milk Composition
NCT07343908
Nebulized AER101 in Pre-op NSCLC
NCT07631299
Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection
NCT07494773
Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia
NCT07554131
Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse
NCT06660017
Topical CBD Scar Healing Study
NCT06129591
Disulfiram in Rheumatoid Arthritis
NCT07534332
Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation
NCT07099638
Feasibility Study for Repurposing RET Inhibitors
NCT07146893
Improving Rates of Diagnostic Colonoscopy in Native Americans
NCT07115875
The Effects of Ketone Supplements With Carbohydrates on Cycling Performance Above Lactate Threshold
NCT07224282
Neuromodulation in Patients With Pulmonary Arterial Hypertension
NCT06802380
Efficacy and Safety Assessment of Experimental Bleaching Agents
NCT06802614
Community Intervention to Improve CVD Risk Factor Control in Young American Indians
NCT06230705
Needle-Free Lidocaine Injection vs Traditional Local Anesthesia in Infant Lumbar Puncture
NCT06552351
The Effect of Intermittent Fasting on Brain Health
NCT06019195
Attitudes and Smoking Perceptions in the Real Environment
NCT06617520
L-Citrulline and Endothelial Function
NCT05722860
Urolithin A Supplementation in Middle-aged Adults With Obesity
NCT05921266
Bariatric Education for Women With Obesity and Endometrial Cancer
NCT05396794
Cognitive-Behavioral Therapy for Children With Nightmares
NCT06033781
Psychological Intervention Using Smartphone Technology to Alleviate Malignant Pain
NCT05774197
NAD Supplementation and Vascular Health in PAD
NCT06534944
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT05523440
Effect of Gabapentin on Post-Operative Pain in Minimally Invasive Sacrocolpopexy
NCT05609682
Cerebromicrovascular Effects of Time-Restricted Eating in Older Adults
NCT05488652
Promoting Resilience and Lowering Risk in Early Childhood
NCT05479734
E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services
NCT03743532
Testing a Novel Smartphone Application for Smoking Cessation With the Oklahoma Helpline
NCT05539209
Empowering LGBTQ+ Tobacco Cessation Pilot
NCT05365633
PARP Inhibition for Gliomas (PI-4G or π4g)
NCT05297864
Nicotine Withdrawal and Reward Processing
NCT05041959
Optoacoustic Detection of Inflammation Using MSOT Device
NCT05333978
CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19)
NCT05236270
Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
NCT05095779
Sensory-Play Based (SenPlay) Intervention for Young Children With or At Risk for ADHD
NCT05222321
Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments
NCT05174949
Holistic Assessment of Tulsa Children's Health
NCT04158089
Exemplar: Determining the Best Practices for EMA Studies
NCT05194228
Mineralized and Partial Demineralized Dentin Graft Compared to FDBA
NCT05311735
PHF Problematic Sexual Behavior of Youth Family Engagement
NCT04902287
Clinical Validation of the AliveCor Kardia 12L and 6L Devices
NCT05053243
Evaluation of Vibration-based Wearable Upper Limb Rehabilitation Device
NCT04698369
Cigarette Smoking Among Young Adults
NCT04340947
Osseodensification and Implant Survival and Success
NCT04741594
TAR 2 Weeks vs 6 Weeks Post-Operative Weight-Bearing
NCT04709861
Intravaginal Devices for Pelvic Floor Motion
NCT04826939
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 40 |
| Phase 3 | 8 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the University of Oklahoma pipeline
80 recruiting of 358 indexed (22% open); 196 completed (55%).
Phase mix: 26 late (III/IV) vs 88 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Oklahoma: open-pipeline peers nationwide
Peers matched on 358 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 358 trials (± recruiting share)
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of Arizona · 349 trials · 16% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this University of Oklahoma page
358 registered trials is a research-attention snapshot, not an endorsement of University of Oklahoma or any single study.
- 80 of University of Oklahoma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Oklahoma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Oklahoma pipeline card: 358 registered trials from official public datasets.Report a data error.